Avsnitt
-
Host: Jennifer Caudle, DO
Guest: Patricia A. Mangan, RN, MSN, APRN-BC
The expansion of treatment options and strategies across the disease continuum is good news for patients who previously had few options; however, it can be a challenge for clinicians to stay up–to date in this very dynamic setting.
-
Host: Jennifer Caudle, DO
Guest: Geoffrey B. Johnson, M.D., Ph.D.
Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it’s going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.
-
Saknas det avsnitt?
-
Guest: Brianna Cagle
The Discovery Team at Perspective has developed a compound, called PSV-359, which is a cyclic peptide radiopharmaceutical. It targets a protein, called fibroblast activation protein (FAP), which is a pan-cancer target and is expressed in a wide variety of cancers. To learn more about her presentation from SNMMI 2024, hear from Brianna Cagle, Research Scientist at Perspective Therapeutics in Iowa.
-
Guest: Chi Liu, PhD
The field of artificial intelligence in nuclear medicine is evolving quickly with new models and approaches. Tune in with Dr. Chi Liu, Professor of Radiology and Biomedical Engineering at Yale University, to hear more about his presentation from SNMMI 2024.
-
Guest: Geoffrey B. Johnson, M.D., Ph.D.
Clinicians are hopeful that theranostics could help treat patients as soon as they go metastatic or even before surgery to try to affect their therapy and possibly get them to avoid having to take toxic or high side effect therapies. To hear more, tune in with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota.
-
Guest: Joyita Dutta
The AI landscape is evolving at a rapid pace. However, there is a shortage of large public data sets in nuclear medicine that AI models can be trained on. To learn more about what’s on the AI horizon and the challenges that are associated, join Dr. Joyita Dutta, Associate Professor at the University of Massachusetts, Amherst in the Department of Biomedical Engineering, who also presented this at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.
-
Host: Brian P. McDonough, MD, FAAFP
Guest: Nima Nabavizadeh, MD
Guest: Tomasz Beer, MD, FACP
While multi-cancer early detection (MCED) testing has the potential to significantly impact the way we approach cancer screening, it’s important to be aware of the risks associated with it, like overdiagnosis. That’s why Drs. Nima Nabavizadeh and Tom Beer join Dr. Brian McDonough to discuss the advantages and drawbacks of MCED testing and how we can mitigate the risk of overdiagnosis. Dr. Nabavizadeh is an Associate Professor in the Department of Radiation Medicine in the School of Medicine at OHSU in Portland, Oregon, and Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.
-
Guest: Lillian Siu, MD, FRCPC
With a few studies in the works for cancer vaccines, the future is exciting for what this could mean for oncology patients. Dive in to learn about the various ways to package cancer vaccines so they can be delivered to patients effectively. And to learn more about the limitations, targets, and platforms of cancer vaccines, which was the topic of her presentation at the American Society of Clinical Oncology 2024 Conference, hear from Dr. Lillian Siu, Senior Medical Oncologist at the Princess Margaret Cancer Centre and Professor of Medicine at the University of Toronto.
-
Guest: Lillian Siu, MD, FRCPC
Since cancer vaccines have been of interest to oncologists for decades, they’ve been trying to figure out how to prime or stimulate the immune system to attack cancer, and until the last few years, cancer vaccines have been challenging. To learn about this unique area of study, which she also presented at ASCO 2024, join Dr. Lillian Siu, Senior Medical Oncologist at the Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto.
-
Guest: Tyler J Bradshaw, PhD
In recent years, doctors have become interested in how large language models and AI technologies could potentially improve radiology overall. Even though these technologies are still in the beginning stages of being used in medicine, eventually doctors hope to show what impact they could have on patients. To learn more about these new technologies and imaging agents, join Dr. Tyler Bradshaw, Assistant Professor in the Department of Radiology at the University of Wisconsin-Madison, who presented this topic at the SNMMI 2024 Annual Meeting.
-
Guest: Ashley L. Sumrall, MD
Advocacy is rooted in patients telling their stories, and every patient can be an advocate to help and allow others to hear about their experience. This has also helped clinicians get the medicine they need for their patients. Dive in to hear how you can incorporate advocacy strategies into your practice with Dr. Ashley Sumrall, Neuro- and Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.
-
Guest: Ashley L. Sumrall, MD
If we want to ensure that we and our patients have healthcare when we’re older and it continues to be available, it’s important to take a stand and be a part of advocacy work. There are multiple ways to get involved, and it’s not as intimidating as someone might think, so to share some of these strategies and the impact it could have on the future of healthcare, join Dr. Ashely Sumrall, Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.
-
Host: Joseph Kim, MD, MPH
This video brief will discuss quality improvement in myelofibrosis management. To highlight ways to improve care for patients with both primary and secondary myelofibrosis, we’ll examine the experiences of two cancer centers that engaged in quality improvement programs.
Molecular Testing Symptom Assessment Prognostic Risk Assessment JAK Inhibitor Therapy Shared Decision-Making Interprofessional Team-Based Care Coordination -
Guest: Lori J. Wirth, MD
Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston.
References:
Gormley M, et al. Br Dent J. 2022;233(9):780-786. Barsouk A, et al. Med Sci (Basel). 2023;11(2):42.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
US-NONO-00581 05/2024 -
Tune in ahead of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting in Toronto for a preview of what to expect with Dr. Munir Ghesani, Chief Medical Officer and the Medical Director at United Theranostics in Princeton, New Jersey.
-
Host: Jennifer Caudle, DO
Guest: Joyce O'Shaughnessy, MD
The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
-
Host: Brian P. McDonough, MD, FAAFP
Guest: Frank Diehl, PhD
A poster presented at the 2024 American Association for Cancer Research Annual Meeting showcased findings from the ASCEND 2 study, which examined the performance of a multi-cancer early detection (MCED) test design that included methylation and protein biomarkers. The study found that this test design achieved overall sensitivity of 50.9 percent for all cancers at a high specificity of 98.5 percent. Dive further into these results and what they might mean for early cancer detection with Dr. Brian McDonough and Dr. Frank Diehl, Senior Vice President of Multi Cancer Early Detection at Exact Sciences Corporation.
-
Host: Javier Cortes, MD, PhD
Guest: Komal Jhaveri, MD, FACP
The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.
-
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
-
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
- Visa fler